Enliven Therapeutics, Inc.

NasdaqGS ELVN

Enliven Therapeutics, Inc. Free Cash Flow Yield on January 14, 2025: -6.86%

Enliven Therapeutics, Inc. Free Cash Flow Yield is -6.86% on January 14, 2025, a 43.47% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Enliven Therapeutics, Inc. 52-week high Free Cash Flow Yield is -5.25% on January 06, 2025, which is 23.37% above the current Free Cash Flow Yield.
Enliven Therapeutics, Inc. 52-week low Free Cash Flow Yield is -12.84% on January 17, 2024, which is -87.29% below the current Free Cash Flow Yield.
Enliven Therapeutics, Inc. average Free Cash Flow Yield for the last 52 weeks is -7.55%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqGS: ELVN

Enliven Therapeutics, Inc.

CEO	Mr. Samuel S. Kintz M.B.A.
IPO Date	March 12, 2020
Location	United States
Headquarters	6200 Lookout Road
Employees	46
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Key trends

Past 5 years